<DOC>
	<DOCNO>NCT00606060</DOCNO>
	<brief_summary>Phase III study , evaluate efficacy safety continuous infusion rFVIII-FS treatment patient hemophilia A undergoing major elective surgery achieving require therapeutic concentration .</brief_summary>
	<brief_title>BAY14-2222 Continuous Infusion Surgeries</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( FVIII : C &lt; /=1 % ) No history FVIII inhibitor formation current evidence inhibitor antibody ( Bethesda Assay &lt; 0.6 BU ) Elective major surgery require least 6 day rFVIIIFS therapy Subjects previously treat FVIII concentrate least 150 exposure day . Previous treatment could type rFVIII plasmaderived FVIII concentrate cryoprecipitate Abnormal renal function ( serum creatinine &gt; 1.3 mg/dL ) Any treatment , may change clearance FVIII ( dialysis , plasma exchange ) Anemia ( hemoglobin &lt; 11 g/dL ) Known AIDS ( HIV seropositive patient may enrol ) Active liver disease ( transaminases &gt; 5 time upper limit normal ) History severe reaction FVIII concentrate Interferon treatment within last 3 month Thrombocytopenia ( &lt; 100,000 platelets/mm3 ) know hematological/bleeding problem hemophilia A Intake investigational drug within 1 month prior study entry Need premedication FVIII infusion ( e.g . antihistamine ) Diastolic blood pressure &gt; 100 mm/Hg , could control antihypertensive medication</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Hemophilia ,</keyword>
	<keyword>Continuous Infusion</keyword>
</DOC>